Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients ...

The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an ... development and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for ...

Historic benchmarks for either chemotherapy agent alone are 23% ORR ... a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in patients with non-small ...

and chemotherapy. The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a ...

Historic benchmarks for either chemotherapy agent alone are 23% ORR ... a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in patients with non-small ...